Introduction Acute coronary syndrome (ACS) remains a leading global cause of mortality and disability despite advances in therapy (1). Dual antiplatelet therapy (DAPT) lowers recurrent ischemic events but leaves a substantial residual thrombotic risk due to persistent thrombin generation (1). Factor XIa, a key enzyme in the intrinsic coagulation pa